These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30311444)

  • 1. Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma.
    Dai J; Huang Q; Niu K; Wang B; Li Y; Dai C; Chen Z; Tao K; Dai J
    Cancer Med; 2018 Nov; 7(11):5691-5703. PubMed ID: 30311444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sestrin 2(SESN2) promotes primary resistance to sorafenib by activating AKT in hepatocellular carcinoma cells].
    Dai J; Niu K; Wang B; Li Y; Xia C; Tao K; Dai J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 May; 34(5):427-433. PubMed ID: 30043734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
    Wu J; Chai H; Li F; Ren Q; Gu Y
    Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
    Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
    Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
    Deng L; Sun J; Chen X; Liu L; Wu D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction.
    Zhu Y; Xu J; Hu W; Wang F; Zhou Y; Xu W; Gong W; Shao L
    Gene; 2020 Aug; 753():144807. PubMed ID: 32461017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Y-box binding protein 1 augments sorafenib resistance
    Liu T; Xie XL; Zhou X; Chen SX; Wang YJ; Shi LP; Chen SJ; Wang YJ; Wang SL; Zhang JN; Dou SY; Jiang XY; Cui RL; Jiang HQ
    World J Gastroenterol; 2021 Jul; 27(28):4667-4686. PubMed ID: 34366628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
    Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
    Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
    [No Abstract]   [Full Text] [Related]  

  • 10. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. l-Methionine potentiates anticancer activity of Sorafenib by epigenetically altering DUSP3/ERK pathway in hepatocellular carcinoma.
    Pal S; Kabeer SW; Sharma S; Tikoo K
    J Biochem Mol Toxicol; 2024 Mar; 38(3):e23663. PubMed ID: 38367245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma.
    Liu J; Qiu WC; Shen XY; Sun GC
    Math Biosci Eng; 2019 Jul; 16(6):6319-6334. PubMed ID: 31698564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing
    Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
    Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
    Long Q; Zou X; Song Y; Duan Z; Liu L
    Biochem Biophys Res Commun; 2019 Jun; 513(3):642-650. PubMed ID: 30981500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
    Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
    Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
    PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.